DoP is implementing PLI Scheme for Pharma with total financial outlay of Rs 15,000 crore: MoS for Chemicals and Fertilizers
New Delhi: The Department of Pharmaceuticals is implementing the Production Linked Incentive (PLI) Scheme for Pharmaceuticals with a total financial outlay of Rs. 15,000 crore and scheme tenure up to FY 2027-28.
This was stated by the Union Minister of State for Chemicals and Fertilizers Smt Anupriya Patel in Lok Sabha in reply to a question.
The scheme provides for financial incentive to 55 selected applicants for manufacturing of identified products under three categories for a period of six years. The product Category 1 covers drugs such as bio-pharmaceuticals, complex generics, gene therapy drugs, complex excipients, orphan drugs etc. Orphan drugs are those drugs which are used for treatment of rare diseases. Under the scheme, total 8 orphan drugs have been approved for manufacturing, the Minister further added.
The 8 orphan drugs approved include Nitisinone indicated for treatment of Hereditary Tyrosinemia Type 1, Cannabidiol indicated for Dravet-Lennox Gastaut syndrome, Nusinersen to treat Spinal Muscular Atrophy.
The orphan drugs approved under the PLI scheme for Pharmaceuticals are as follows:
S. No. | Name of the product | Usage |
1 | Nitisinone | Treatment of Hereditary Tyrosinemia Type 1 |
2 | Nusinersen | Treatment of Spinal Muscular Atrophy |
3 | Rufinamide | Treatment of Lennox-Gastaut syndrome. |
4 | Sodium Phenyl Butyrate | Treatment of Urea Cycle Disorders |
5 | Tiopronin | Prevention of Cystine Nephrolithiasis |
6 | Trientine Hydrochloride | Treatment of Wilson's disease |
7 | Eliglustat | Treatment of Gaucher’s disease |
8 | Cannabidiol | Treatment of Dravet-Lennox Gastaut syndrome |
Read also: JP Nadda says Govt vigilant about quality of medicines
